Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

BXBing XiangAZAilin ZhaoTNTing Niu

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds golidocitinib improves HLH and exhibits anti-tumor activity in relapsed PTCL cases, indicating promise for future therapy.

Key Points

  • Evaluate the efficacy and safety of golidocitinib in treating patients with PTCL-associated HLH.
  • Retrospective single-center study
  • Involved 16 patients with relapsed/refractory PTCL-associated HLH
  • Patients received golidocitinib with or without chemotherapy
  • Lymphoma and HLH responses assessed according to Lugano 2014 and HLH-2004 criteria respectively.
  • Overall response rate was 46.7% in lymphoma treatment
  • 85.7% HLH response at week 2
  • Significant reductions in inflammatory markers including IL-6 and ferritin
  • No treatment-related deaths reported
  • 62.5% of patients remained on treatment at last follow-up.

Cite This Study

Xiang et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d549https://doi.org/10.1182/blood-2025-6303
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Preliminary efficacy and safety of golidocitinib in relapsed/refractory T cell and NK cell large granular lymphocyte leukemia2025
  2. 2Durable responses in the updated 2-year follow-up of patients from a single-center with Relapsed/Refractory peripheral T-cell lymphoma treated with golidocitinib2025
  3. 3Golidocitinib combination therapy as first-line treatment in PTCL: Retrospective data from a single centre2025
  4. 4Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial2025 · 1 citations
  5. 5Golidocitinib was used for the first time to treat refractory NK-Large Granular lymphocytic leukemia with a STAT3 mutation, accompanied by hemolytic anemia: a case report.2025 · 3 citations